Selected article for: "care require and health risk"
Author: Qeadan, Fares; Tingey, Benjamin; Bern, Rona; Porucznik, Christina A; English, Kevin; Saeed, Ali I.; Madden, Erin Fanning
Title: Opioid use disorder and health service utilization among COVID-19 patients in the US: A nationwide cohort from the Cerner Real-World Data
  • Cord-id: h2pk36s1
  • Document date: 2021_6_4
    • ID: h2pk36s1
    Snippet: BACKGROUND: Both opioid use and COVID-19 affect respiratory and pulmonary health, potentially putting individuals with opioid use disorders (OUD) at risk for complications from COVID-19. We examine the relationship between OUD and subsequent hospitalization, length of stay, risk for invasive ventilator dependence (IVD), and COVID-19 mortality. METHODS: Multivariable logistic and exponential regression models using electronic health records data from the Cerner COVID-19 De-Identified Data Cohort
    Document: BACKGROUND: Both opioid use and COVID-19 affect respiratory and pulmonary health, potentially putting individuals with opioid use disorders (OUD) at risk for complications from COVID-19. We examine the relationship between OUD and subsequent hospitalization, length of stay, risk for invasive ventilator dependence (IVD), and COVID-19 mortality. METHODS: Multivariable logistic and exponential regression models using electronic health records data from the Cerner COVID-19 De-Identified Data Cohort from January through June 2020. FINDINGS: Out of 52,312 patients with COVID-19, 1.9% (n=1,013) had an OUD. COVID-19 patients with an OUD had higher odds of hospitalization (aOR=3.44, 95% CI=2.81–4.21), maximum length of stay ([Formula: see text] =1.16, 95% CI=1.09–1.22), and odds of IVD (aOR=1.26, 95% CI=1.06–1.49) than patients without an OUD, but did not differ with respect to COVID-19 mortality. However, OUD patients under age 45 exhibited greater COVID-19 mortality (aOR=3.23, 95% CI=1.59–6.56) compared to patients under age 45 without an OUD. OUD patients using opioid agonist treatment (OAT) exhibited higher odds of hospitalization (aOR=5.14, 95% CI=2.75–10.60) and higher maximum length of stay ([Formula: see text] =1.22, 95% CI=1.01–1.48) than patients without OUDs; however, risk for IVD and COVID-19 mortality did not differ. OUD patients using naltrexone had higher odds of hospitalization (aOR=32.19, 95% CI=4.29–4,119.83), higher maximum length of stay ([Formula: see text] =1.59, 95% CI=1.06–2.38), and higher odds of IVD (aOR=3.15, 95% CI=1.04–9.51) than patients without OUDs, but mortality did not differ. OUD patients who did not use treatment medication had higher odds of hospitalization (aOR=4.05, 95% CI=3.32–4.98), higher maximum length of stay ([Formula: see text] =1.14, 95% CI=1.08–1.21), and higher odds of IVD (aOR=1.25, 95% CI=1.04–1.50) and COVID-19 mortality (aOR=1.31, 95% CI=1.07–1.61) than patients without OUDs. INTERPRETATION: This study suggests people with OUD and COVID-19 often require higher levels of care, and OUD patients who are younger or not using medication treatment for OUDs are particularly vulnerable to death due to COVID-19.

    Search related documents:
    Co phrase search for related documents
    • access utilization and accountability insurance portability act: 1
    • access utilization and logistic regression: 1, 2, 3
    • access utilization and los regression: 1
    • access utilization and low income: 1, 2, 3, 4, 5
    • access utilization and low utilization: 1, 2, 3
    • acute ards respiratory distress syndrome and adjusted analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and adjusted model: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and adjusted odd: 1
    • acute ards respiratory distress syndrome and adjusted odd ratio: 1
    • acute ards respiratory distress syndrome and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and liver kidney disease: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and logistic model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and low income: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11